B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny

Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long‐Term Effects on Serum Immunoglobulins

“…Immune dysregulation in patients with SLE is at least partly related to changes in the interactions between immune cells within germinal centers and altered trafficking of peripheral blood lymphocytes 25, 26. Some abnormalities in the composition of peripheral B cell phenotypes appear to “improve” following rituximab, but this may also reflect naive B cell return, which recapitulates ontogeny 27, 28. Reduced levels of possibly protective natural antibodies of the IgM class have been suggested to be associated with development of anti‐dsDNA antibodies in a murine model of SLE 29.…”

Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT

“…[20][21][22][23] Laboratory studies in patients with lymphoma or alloantibodies before kidney transplantation have shown a delayed recovery of CD19 þ /CD27 þ B-memory cells and impaired isotype expression following rituximab therapy as seen in patients with common variable immunodeficiency, suggesting that rituximab can affect not only B-cell quantities but also the recovery of functional B-cell repertoires and differentiation into plasma cells. 20,21,24,25 Little is known of the consequences of rituximab therapy on B-lymphocyte depletion and recovery in patients with PTLD following allogeneic HSCT, particular in pediatric patients. Although incubation of B cells with anti-CD20 antibody depletes normal circulating B cells and has variable effects on cell cycle progression and signaling, the detailed biologic functions of CD20 remain uncertain.…”

“…), administered on days þ 1, þ 3, þ 6, þ 11. Primary engraftment was achieved in all patients and occurred after a median of 22.5 days (range, [16][17][18][19][20][21][22][23][24][25][26][27][28]; two patients had secondary graft failure at days 98 and 225 (patient nos. 2 and 4).…”

Immunological changes in diffuse large B-cell lymphomas after Rituximab-CHOP treatment: Own data and review of the literature

“…pozitivitást is mutatnak, ami a tranzicionális B-sejtekre jellemző [6]. A CD38 pozitivitás arra utal, hogy ezek fiatal, csontvelői eredetű B-sejtek, melyek -a CD24 pozitivitás alapján-még nem estek át a centrum germinatívumban lezajló érésen.…”

“…A B-és a T-sejtek felszínén is megnőhet a CD95 expresszió, a memória típusú T-sejtek aránya növekszik, míg a naív T-sejteké pedig csökken [7]. Ezek az eltérések (IgD -CD27 + memória B-sejtek hiánya, hypogammaglobulinaemia, fokozott CD95 expresszió, naív T-sejtek arányának csökkenése) összességében a common variábilis immundefficienciához (CVID) hasonló állapotot tükröznek, és az immunrendszer éretlenségére utalnak [6,7,9].…”